Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August9, 2017, we issued a press release reporting our financial results for the second quarter ended June30, 2017.The full text of the press release is attached as exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B-2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
Description |
|
99.1 |
Press release issued August 9, 2017, reporting financial results for the second quarter ended June 30, 2017. |
Cidara Therapeutics, Inc. ExhibitEX-99.1 2 earningsrelease.htm EARNINGS RELEASE Exhibit Exhibit 99.1FOR IMMEDIATE RELEASECidara Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsSAN DIEGO,…To view the full exhibit click here
About Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.
